Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (REALISTIC)
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Expanded Access
Expanded Access
Available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Locations
-
-
-
Calgary, Canada
-
Mississauga, Canada
-
Newmarket, Canada
-
Sainte Foy, Canada
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
Kitchener, Ontario, Canada
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
Windsor, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
Rimouski, Quebec, Canada
-
Trois-Rivires, Quebec, Canada
-
-
-
-
-
Amiens, France
-
Cahors, France
-
Corbeil Essonnes, France
-
Dreux, France
-
Lievin, France
-
Montpellier, France
-
Mulhouse, France
-
Nantes, France
-
Orleans, France
-
Paris, France
-
Pierre-Benite, France
-
Rennes, France
-
Saint Priest en Jarez, France
-
-
-
-
-
Bad Neuenahr, Germany
-
Baden, Germany
-
Berlin, Germany
-
Chemnitz, Germany
-
Dresden, Germany
-
Duisburg, Germany
-
Erfurt, Germany
-
Erlangen, Germany
-
Freiburg, Germany
-
Friedrichroda, Germany
-
Goslar, Germany
-
Hamburg, Germany
-
Hildesheim, Germany
-
Hoyerswerda, Germany
-
Jena, Germany
-
Kiel, Germany
-
Koln, Germany
-
Leipzig, Germany
-
Mainz, Germany
-
Munchen, Germany
-
Neuss, Germany
-
Osnabruck, Germany
-
Rostock, Germany
-
Wiesbaden, Germany
-
Zerbst, Germany
-
-
-
-
-
Bologna, Italy
-
Genova, Italy
-
Jesi, Italy
-
Modena, Italy
-
Palermo, Italy
-
Pisa, Italy
-
Prato, Italy
-
Siena, Italy
-
Udine, Italy
-
-
-
-
-
Apeldoorn, Netherlands
-
Arnhem, Netherlands
-
Den-Haag, Netherlands
-
Leiden, Netherlands
-
-
-
-
-
Barcelona, Spain
-
Coruna, Spain
-
La Laguna, Spain
-
Madrid, Spain
-
Murcia, Spain
-
Oviedo, Spain
-
Pontevedra, Spain
-
Sabadell, Spain
-
Salamanca, Spain
-
Santander, Spain
-
Santiago de Compostela, Spain
-
Torrelavega, Spain
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Montgomery, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
Tucson, Arizona, United States
-
-
Arkansas
-
Hot Springs, Arkansas, United States
-
Little Rock, Arkansas, United States
-
-
California
-
Fullerton, California, United States
-
La Jolla, California, United States
-
Los Angeles, California, United States
-
Palm Desert, California, United States
-
Sacramento, California, United States
-
Santa Barbara, California, United States
-
Santa Maria, California, United States
-
Tustin, California, United States
-
Westlake Village, California, United States
-
Whittier, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Danbury, Connecticut, United States
-
Trumbull, Connecticut, United States
-
-
Delaware
-
Lewes, Delaware, United States
-
Newark, Delaware, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Boca Raton, Florida, United States
-
Delray Beach, Florida, United States
-
Gainesville, Florida, United States
-
Jacksonville, Florida, United States
-
Orlando, Florida, United States
-
South Miami, Florida, United States
-
Tampa, Florida, United States
-
Tavares, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Idaho
-
Coeur d'Alene, Idaho, United States
-
Idaho Falls, Idaho, United States
-
-
Illinois
-
Maywood, Illinois, United States
-
Peoria, Illinois, United States
-
Rock Island, Illinois, United States
-
Springfield, Illinois, United States
-
-
Indiana
-
Evansville, Indiana, United States
-
Indianapolis, Indiana, United States
-
-
Kansas
-
Wichita, Kansas, United States
-
-
Kentucky
-
Louisville, Kentucky, United States
-
-
Louisiana
-
Covington, Louisiana, United States
-
Lake Charles, Louisiana, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
Columbia, Maryland, United States
-
Frederick, Maryland, United States
-
Wheaton, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
Fall River, Massachusetts, United States
-
-
Michigan
-
Battle Creek, Michigan, United States
-
Kalamazoo, Michigan, United States
-
Lansing, Michigan, United States
-
Petoskey, Michigan, United States
-
-
Minnesota
-
Duluth, Minnesota, United States
-
Rochester, Minnesota, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
New Jersey
-
New Brunswick, New Jersey, United States
-
Voorhees, New Jersey, United States
-
-
New York
-
Albany, New York, United States
-
Bronx, New York, United States
-
New York, New York, United States
-
Orchard Park, New York, United States
-
Rochester, New York, United States
-
Roslyn, New York, United States
-
Smithtown, New York, United States
-
Syracuse, New York, United States
-
-
North Carolina
-
Asheville, North Carolina, United States
-
Chapel Hill, North Carolina, United States
-
Charlotte, North Carolina, United States
-
Monroe, North Carolina, United States
-
Wilmington, North Carolina, United States
-
-
Ohio
-
Columbus, Ohio, United States
-
Dayton, Ohio, United States
-
Fairfield, Ohio, United States
-
Mayfield, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Pennsylvania
-
Erie, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
West Reading, Pennsylvania, United States
-
Wexford, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
-
Tennessee
-
Jackson, Tennessee, United States
-
-
Texas
-
Amarillo, Texas, United States
-
Austin, Texas, United States
-
Dallas, Texas, United States
-
Fort Worth, Texas, United States
-
Houston, Texas, United States
-
Lubbock, Texas, United States
-
San Antonio, Texas, United States
-
Sugar Land, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Virginia
-
Newport News, Virginia, United States
-
Richmond, Virginia, United States
-
-
Washington
-
Spokane, Washington, United States
-
Tacoma, Washington, United States
-
Yakima, Washington, United States
-
-
West Virginia
-
Clarksburg, West Virginia, United States
-
-
Wisconsin
-
Glendale, Wisconsin, United States
-
Milwaukee, Wisconsin, United States
-
Monroe, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patient with established moderate to severe rheumatoid arthritis
Exclusion Criteria:
- All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment
- Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10.
At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
|
|
Experimental: Certolizumab pegol (CZP)
|
400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10.
At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
American College of Rheumatology 20% (ACR20) Response at Week 12
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Concomitant Methotrexate (MTX) Use.
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects Without Concomitant Methotrexate (MTX) Use.
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Prior Anti-tumor Necrosis (Anti-TNF) Use
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects Without Prior Anti-tumor Necrosis (Anti-TNF) Use
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Disease Duration < 2 Years
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 20% (ACR20) Response at Week 12 for Subjects With Disease Duration ≥ 2 Years.
Time Frame: Baseline, Week 12
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 50% (ACR50) Response at Week 12
Time Frame: Baseline, Week 12
|
ACR50 responders are subjects with at least 50% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
American College of Rheumatology 70% (ACR70) Response at Week 12.
Time Frame: Baseline, Week 12
|
ACR70 responders are subjects with at least 70% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS)
|
Baseline, Week 12
|
|
Change From Baseline in DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] at Week 12
Time Frame: Baseline, Week 12
|
DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm).
A lower score indicates less disease activity.
Change from baseline is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12
Time Frame: Baseline, Week 12
|
SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
Change from baseline is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12
Time Frame: Baseline, Week 12
|
CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
Change from baseline is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] Remission (<2.6) at Week 12
Time Frame: Week 12
|
DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm).
A lower score indicates less disease activity.
|
Week 12
|
|
SDAI (Simplified Disease Activity Index) Remission (≤3.3) at Week 12
Time Frame: Week 12
|
SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
|
Week 12
|
|
CDAI (Clinical Disease Activity Index) Remission (≤2.8) at Week 12
Time Frame: Week 12
|
CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
|
Week 12
|
|
Change From Baseline in Tender Joint Count (TJC) at Week 12
Time Frame: Baseline, Week 12
|
TJC is calculated based on tenderness response of 28 joints.
TJC possible values range from 0 to 28.
A lower TJC indicates less joint tenderness.
Change from baseline is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in Swollen Joint Count (SJC) at Week 12
Time Frame: Baseline, Week 12
|
SJC is calculated based on swelling response of 28 joints.
SJC possible values range from 0 to 28.
A lower SJC indicates less joint swelling.
Change from baseline is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
Time Frame: Baseline, Week 12
|
HAQ-DI is derived based on the mean of individual scores in 8 categories of daily living actives (using 20 questions).
Each question is scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).
Change from baseline is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in C-reactive Protein (CRP) at Week 12
Time Frame: Baseline, Week 12
|
Change from baseline in CRP (mg/L) is computed as the ratio of Week 12 value divided by baseline value.
A ratio less then 1 indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) at Week 12
Time Frame: Baseline, Week 12
|
Change from Baseline in PAAP-VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS) at Week 12
Time Frame: Baseline, Week 12
|
Change from Baseline in PtGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Change From Baseline in Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS) at Week 12
Time Frame: Baseline, Week 12
|
Change from Baseline in PhGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as Week 12 value minus baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was carried out using the Last Observation Carried Forward (LOCF) method.
|
Baseline, Week 12
|
|
Time to Sustained American College of Rheumatology 20% (ACR20) Response
Time Frame: Baseline up to Week 12
|
The time from randomization to sustained ACR20 response at 2 consecutive visits (at the latest on Week 12).
|
Baseline up to Week 12
|
|
European League Against Rheumatism (EULAR) Response at Week 12
Time Frame: Baseline, Week 12
|
EULAR response (good response, moderate response, or no response) is defined based on the present value and improvement from baseline in DAS28(CRP) [Disease Activity Score-28 (C-reactive protein)].
|
Baseline, Week 12
|
|
American College of Rheumatology 20% (ACR20) Response at Week 28
Time Frame: Baseline, Week 28
|
ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).
This analysis was carried out using imputation.
|
Baseline, Week 28
|
|
American College of Rheumatology 50% (ACR50) Response at Week 28
Time Frame: Baseline, Week 28
|
ACR50 responders are subjects with at least 50% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).
This analysis was carried out using imputation.
|
Baseline, Week 28
|
|
American College of Rheumatology 70% (ACR70) Response at Week 28
Time Frame: Baseline, Week 28
|
ACR70 responders are subjects with at least 70% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).
This analysis was carried out using imputation.
|
Baseline, Week 28
|
|
Change From Baseline in DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] at Week 28
Time Frame: Baseline, Week 28
|
DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm).
A lower score indicates less disease activity.
Change from Baseline is computed as the value at Week 28 minus Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 28
Time Frame: Baseline, Week 28
|
SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
Change from Baseline is computed as the value at Week 28 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 28
Time Frame: Baseline, Week 28
|
CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
Change from Baseline is computed as value at Week 28 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
DAS28(CRP) [Disease Activity Score-28 (C-reactive Protein)] Remission (<2.6) at Week 28
Time Frame: Week 28
|
DAS28(CRP) is calculated using tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/L), and Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in mm).
A lower score indicates less disease activity.
This analysis was carried out using imputation.
|
Week 28
|
|
SDAI (Simplified Disease Activity Index) Remission (≤3.3) at Week 28
Time Frame: Week 28
|
SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), C-reactive protein (CRP in mg/dL), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
This analysis was carried out using imputation.
|
Week 28
|
|
CDAI (Clinical Disease Activity Index) Remission (≤2.8) at Week 28
Time Frame: Week 28
|
CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Arthritis-Visual Analog Scale (PtGADA-VAS in cm), and Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS in cm).
A lower score indicates less disease activity.
This analysis was carried out using imputation.
|
Week 28
|
|
Change From Baseline in Tender Joint Count (TJC) at Week 28
Time Frame: Baseline, Week 28
|
TJC is calculated based on tenderness response of 28 joints.
TJC possible values range from 0 to 28.
A lower TJC indicates less joint tenderness.
Change from Baseline is computed as the value at Week 28 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in Swollen Joint Count (SJC) at Week 28
Time Frame: Baseline, Week 28
|
SJC is calculated based on swelling response of 28 joints.
SJC possible values range from 0 to 28.
A lower SJC indicates less joint swelling.
Change from baseline is computed as the value at Week 28 minus the baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 28
Time Frame: Baseline, Week 28
|
HAQ-DI is derived based on the mean of individual scores in 8 categories of daily living actives (using 20 questions).
Each question is scored 0-3 (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do).
Change from baseline is computed as the value at Week 28 minus the baseline value.
A negative value in change from baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in C-reactive Protein (CRP) at Week 28
Time Frame: Baseline, Week 28
|
Change from Baseline in CRP (mg/L) is computed as the ratio of the value at Week 28 divided by Baseline value.
A ratio less then 1 indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) at Week 28
Time Frame: Baseline, Week 28
|
Change from Baseline in PAAP-VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) is computed as the value at Week 28 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS) at Week 28
Time Frame: Baseline, Week 28
|
Change from Baseline in PtGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as the value at Week 28 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
|
Change From Baseline in Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS) at Week 28
Time Frame: Baseline, Week 28
|
Change from Baseline in PhGADA-VAS (0 to 100 mm visual analog scale, 0 being no symptoms and 100 being severe symptoms) is computed as the value at Week 28 minus the Baseline value.
A negative value in change from Baseline indicates an improvement.
This analysis was done using a Mixed Effects Repeated Measures Model (MMRM).
|
Baseline, Week 28
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Pope J, Bingham CO 3rd, Fleischmann RM, Dougados M, Massarotti EM, Wollenhaupt J, Duncan B, Coteur G, Weinblatt ME. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Res Ther. 2015 Nov 27;17:343. doi: 10.1186/s13075-015-0849-1.
- Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther. 2015 Nov 15;17:325. doi: 10.1186/s13075-015-0841-9.
- Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO 3rd, Duncan B, Goel N, Davies OR, Dougados M. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford). 2012 Dec;51(12):2204-14. doi: 10.1093/rheumatology/kes150. Epub 2012 Aug 25.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C87094
- 2008-005427-28 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.